Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Intensive Care Medicine
Published in: Intensive Care Medicine 9/2019

01-09-2019 | Erythropoietin | Systematic Review

Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis

Authors: Edward Litton, Peter Latham, Julia Inman, Jingjing Luo, Peter Allan

Published in: Intensive Care Medicine | Issue 9/2019

Login to get access

Abstract

Purpose

Severe immune dysregulation is common in patients admitted to the intensive care unit (ICU) and is associated with adverse outcomes. Erythropoietin-stimulating agents (ESAs) have immune-modulating and anti-apoptotic effects. However, their safety and efficacy in critically ill patients remain uncertain. We evaluated whether ESAs, administered to critically unwell adult patients admitted to the ICU, reduced mortality at hospital discharge.

Methods

The search strategy was conducted according to a predetermined protocol and included OVID MEDLINE, OVID EMBASE and The Cochrane Central Register of Controlled Trials from inception until 20 May 2019. Publications were eligible for inclusion if they were randomized controlled trials (RCTs) including adult patients admitted to an ICU, that identified and reported a group receiving ESA therapy compared to a group not receiving ESA therapy and reported mortality. There were no language restrictions.

Results

The systematic review included 21 studies with 5452 participants. In-hospital mortality, reported in 16 studies of which only one was at low risk of bias, was lower in the ESA group (276 of 2187 patients, 12.6%) than the comparator group (339 out of 2204 patients, 15.4%), [relative risk (RR) 0.82, 95% CI 0.71–0.94, P = 0.006, I2 = 0.0%]. The RR of SAEs and thromboembolic events for the ESA and comparator groups were similar, RR 1.11 (95% CI 0.94–1.31, P = 0.228, I2 66%) and 1.22 (95% CI 0.95–1.58, P = 0.086, I2 47%), respectively.

Conclusions

In heterogenous populations of critically ill adults, evidence from RCTs of mainly low or unclear quality, suggests that ESA therapy may decrease mortality.
Appendix
Available only for authorised users
Literature
1.
Muszynski JA, Thakkar R, Hall MW (2016) Inflammation and innate immune function in critical illness. Curr Opin Pediatr 28:267–273CrossRefPubMed
2.
Nairz M, Sonnweber T, Schroll A, Theurl I, Weiss G (2012) The pleiotropic effects of erythropoietin in infection and inflammation. Microbes Infect 14:238–246CrossRefPubMedPubMedCentral
3.
DeAngelo AJ, Bell DG, Quinn MW, Long DE, Ouellette DR (2005) Erythropoietin response in critically ill mechanically ventilated patients: a prospective observational study. Crit Care 9:R172–176CrossRefPubMedPubMedCentral
4.
Krafte-Jacobs B, Levetown ML, Bray GL, Ruttimann UE, Pollack MM (1994) Erythropoietin response to critical illness. Crit Care Med 22:821–826CrossRefPubMed
5.
6.
Peng W, Xing Z, Yang J, Wang Y, Wang W, Huang W (2014) The efficacy of erythropoietin in treating experimental traumatic brain injury: a systematic review of controlled trials in animal models. J Neurosurg 121:653–664CrossRefPubMed
7.
Ranjbaran M, Kadkhodaee M, Seifi B, Mirzaei R, Ahghari P (2018) Resuscitative therapy with erythropoietin reduces oxidative stress and inflammatory responses of vital organs in a rat severe fixed-volume hemorrhagic shock model. Gen Physiol Biophys 37:83–92CrossRefPubMed
8.
Rocha J, Eduardo-Figueira M, Barateiro A, Fernandes A, Brites D, Pinto R, Freitas M, Fernandes E, Mota-Filipe H, Sepodes B (2015) Erythropoietin reduces acute lung injury and multiple organ failure/dysfunction associated to a scald-burn inflammatory injury in the rat. Inflammation 38:312–326CrossRefPubMed
9.
10.
Corwin HL, Gettinger A, Fabian TC, May A, Pearl RG, Heard S, An R, Bowers PJ, Burton P, Klausner MA, Corwin MJ, Group EPOCCT (2007) Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 357:965–976CrossRefPubMed
11.
Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J (2012) Erythropoietin or darbepoetin for patients with cancer. Cochrane Datab Syst Rev 12:CD003407
12.
Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators C (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085–2098CrossRefPubMed
13.
Fishbane S, Besarab A (2007) Mechanism of increased mortality risk with erythropoietin treatment to higher hemoglobin targets. Clin J Am Soc Nephrol CJASN 2:1274–1282CrossRefPubMed
14.
Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151(264–269):W264CrossRef
15.
Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods G, Cochrane Statistical Methods G (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefPubMedPubMedCentral
16.
Lykissas MG, Korompilias AV, Vekris MD, Mitsionis GI, Sakellariou E, Beris AE (2007) The role of erythropoietin in central and peripheral nerve injury. Clin Neurol Neurosurg 109:639–644CrossRefPubMed
17.
Abrishamkar S, Safavi M, Honarmand A (2012) Effect of erythropoietin on Glasgow Coma Scale and Glasgow Outcome Sale in patient with diffuse axonal injury. J Res Med Sci 17:51–56PubMedPubMedCentral
18.
Aloizos S, Evodia E, Gourgiotis S, Isaia EC, Seretis C, Baltopoulos GJ (2015) Neuroprotective effects of erythropoietin in patients with severe closed brain injury. Turk Neurosurg 25:552–558PubMed
19.
Bai XF, Gao YK (2018) Recombinant human erythropoietin for treating severe traumatic brain injury. Medicine (Baltimore) 97:e9532CrossRef
20.
Cariou A, Deye N, Vivien B, Richard O, Pichon N, Bourg A, Huet L, Buleon C, Frey J, Asfar P, Legriel S, Narcisse S, Mathonnet A, Cravoisy A, Dequin PF, Wiel E, Razazi K, Daubin C, Kimmoun A, Lamhaut L, Marx JS, de la Garanderie DP, Ecollan P, Combes A, Spaulding C, Barat F, Ben Boutieb M, Coste J, Chiche JD, Pene F, Mira JP, Treluyer JM, Hermine O, Carli P, Epo ACRSG (2016) Early high-dose erythropoietin therapy after out-of-hospital cardiac arrest: a multicenter, randomized controlled trial. J Am Coll Cardiol 68:40–49CrossRefPubMed
21.
Corwin HL, Gettinger A, Rodriguez RM, Pearl RG, Gubler KD, Enny C, Colton T, Corwin MJ (1999) Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. Crit Care Med 27:2346–2350CrossRefPubMed
22.
Corwin HL, Gettinger A, Pearl RG et al (2002) Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA J Am Med Assoc 288:2827–2835CrossRef
23.
de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P (2012) Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. BMC Nephrol 13:132CrossRefPubMedPubMedCentral
24.
Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, Westhuyzen J, Celi LA, McGinley RJ, Campbell IJ, George PM (2010) Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Kidney Int 77:1020–1030CrossRefPubMed
25.
Gabriel A, Kozek S, Chiari A, Fitzgerald R, Grabner C, Geissler K, Zimpfer M, Stockenhuber F, Bircher NG (1998) High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 44:361–367CrossRefPubMed
26.
Georgopoulos D, Matamis D, Routsi C, Michalopoulos A, Maggina N, Dimopoulos G, Zakynthinos E, Nakos G, Thomopoulos G, Mandragos K, Maniatis A, Critical Care Clinical Trials Greek G (2005) Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. Crit Care 9:R508–R515CrossRefPubMedPubMedCentral
27.
Gerasimov L (2012) Use of erythropoietin in patients with injury and blood loss. General Reanimatol 8:11–17CrossRef
28.
Li ZM, Xiao YL, Zhu JX, Geng FY, Guo CJ, Chong ZL, Wang LX (2016) Recombinant human erythropoietin improves functional recovery in patients with severe traumatic brain injury: a randomized, double blind and controlled clinical trial. Clin Neurol Neurosurg 150:80–83CrossRefPubMed
29.
Luchette FA, Pasquale MD, Fabian TC, Langholff WK, Wolfson M (2012) A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the long term trauma outcomes study. Am J Surg 203:508–516CrossRefPubMed
30.
Nichol A, French C, Little L, Haddad S, Presneill J, Arabi Y, Bailey M, Cooper DJ, Duranteau J, Huet O, Mak A, McArthur C, Pettila V, Skrifvars M, Vallance S, Varma D, Wills J, Bellomo R, Investigators E-T, Group ACT (2015) Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial. Lancet 386:2499–2506CrossRefPubMed
31.
32.
Robertson CS, Hannay HJ, Yamal JM, Gopinath S, Goodman JC, Tilley BC, Epo Severe TBITI, Baldwin A, Rivera Lara L, Saucedo-Crespo H, Ahmed O, Sadasivan S, Ponce L, Cruz-Navarro J, Shahin H, Aisiku IP, Doshi P, Valadka A, Neipert L, Waguspack JM, Rubin ML, Benoit JS, Swank P (2014) Effect of erythropoietin and transfusion threshold on neurological recovery after traumatic brain injury: a randomized clinical trial. JAMA J Am Med Assoc 312:36–47CrossRef
33.
Silver M, Corwin MJ, Bazan A, Gettinger A, Enny C, Corwin HL (2006) Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial. Crit Care Med 34:2310–2316CrossRefPubMed
34.
Springborg JB, Moller C, Gideon P, Jorgensen OS, Juhler M, Olsen NV (2007) Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 149:1089–1101 (discussion 1101) CrossRef
35.
Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ (2009) Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. Clinical article. J Neurosurg 111:171–180CrossRefPubMed
36.
van Iperen CE, Gaillard CA, Kraaijenhagen RJ, Braam BG, Marx JJ, van de Wiel A (2000) Response of erythropoiesis and iron metabolism to recombinant human erythropoietin in intensive care unit patients. Crit Care Med 28:2773–2778CrossRefPubMed
37.
French CJ, Glassford NJ, Gantner D, Higgins AM, Cooper DJ, Nichol A, Skrifvars MB, Imberger G, Presneill J, Bailey M, Bellomo R (2017) Erythropoiesis-stimulating agents in critically ill trauma patients: a systematic review and meta-analysis. Ann Surg 265:54–62CrossRefPubMed
38.
Mesgarpour B, Heidinger BH, Roth D, Schmitz S, Walsh CD, Herkner H (2017) Harms of off-label erythropoiesis-stimulating agents for critically ill people. Cochrane Datab Syst Rev 8:CD010969
Metadata
Title
Safety and efficacy of erythropoiesis-stimulating agents in critically ill patients admitted to the intensive care unit: a systematic review and meta-analysis
Authors
Edward Litton
Peter Latham
Julia Inman
Jingjing Luo
Peter Allan
Publication date
01-09-2019
Publisher
Springer Berlin Heidelberg
Published in
Intensive Care Medicine / Issue 9/2019
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI
https://doi.org/10.1007/s00134-019-05686-y

Other articles of this Issue 9/2019

Intensive Care Medicine 9/2019 Go to the issue

Editorial

Doing more of less: what registry data tell us about death in PICU

Correspondence

Causal inference in secondary analysis of a randomized controlled trial

Correction

Correction to: Continual hemodynamic monitoring with a single-use transesophageal echocardiography probe in critically ill patients with shock: a randomized controlled clinical trial

Less is More

When less is more in the active management of elevated body temperature of ICU patients

Original

Speckle tracking quantification of lung sliding for the diagnosis of pneumothorax: a multicentric observational study

Correspondence

The lung point, still a sign specific to pneumothorax